

IROBOT CORP  
Form 4  
July 12, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
CAMPANELLO RUSSELL J

(Last) (First) (Middle)

C/O IROBOT CORPORATION, 8  
CROSBY DRIVE

(Street)

BEDFORD, MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
IROBOT CORP [IRBT]

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/10/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_ Other (specify below)  
EVP Human Resources, Corp Comm

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	07/10/2017		M		\$ 24.53	82,434	D
Common Stock	07/10/2017		S <sup>(1)</sup>		\$ 85	75,528	D
Common Stock	07/11/2017		M		\$ 24.53	78,622	D
Common Stock	07/11/2017		S <sup>(1)</sup>		\$ 85	75,528	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 24.53	07/10/2017		M	6,906	<u>(2)</u> 12/30/2017	Common Stock	6,906
Employee Stock Option (Right to Buy)	\$ 24.53	07/11/2017		M	3,094	<u>(2)</u> 12/30/2017	Common Stock	3,094

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CAMPANELLO RUSSELL J C/O IROBOT CORPORATION 8 CROSBY DRIVE BEDFORD, MA 01730			EVP Human Resources, Corp Comm	

## Signatures

/s/ Glen D. Weinstein,  
Attorney-in-Fact

07/12/2017

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2017.

(2) This option is currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays

a currently valid OMB number. h: 73%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

\$40.57

9,237 (Deferred)

\$40.57

3,249 (Matching)

d)

Aggregated information

Aggregated

volume

Price

1

2,486

\$40.57

e)

Date of the transaction

2017-02-16

f)  
Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D E Troy
  - b) Position/status SVP & General Counsel
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

GlaxoSmithKline plc American Depositary Shares ('ADSs')

  - a) Description of the financial instrument ISIN: US37733W1053
  - b) Nature of the transaction The withholding of ADSs to meet tax liabilities further to the vesting of awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
\$40.57	3,280 (Deferred)
\$40.57	1,208 (Matching)

Aggregated information

  - d) Aggregated
 

volume	4,488
Price	\$40.57
  - e) Date of the transaction 2017-02-16
  - f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Explanation of Responses:

Date: February 20, 2017

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc